Journal
DIGESTIVE DISEASES AND SCIENCES
Volume 66, Issue 5, Pages 1639-1649Publisher
SPRINGER
DOI: 10.1007/s10620-020-06381-5
Keywords
Calprotectin; Pregnancy; IBD; Cesarean section; Outcomes; Birth weight
Categories
Funding
- Centre of Excellence for Gastrointestinal Inflammation and Immunity Research (CEGIIR)
- University of Alberta Department of Medicine
- University of Alberta Gastroenterology
Ask authors/readers for more resources
Elevated fecal calprotectin levels during pregnancy in patients with inflammatory bowel disease may be associated with adverse pregnancy outcomes, serving as a potential marker for prediction.
Background The role of fecal calprotectin in predicting pregnancy-related outcomes in inflammatory bowel disease (IBD) remains unknown. Aim To determine whether increased fecal calprotectin during pregnancy is associated with adverse pregnancy outcomes in IBD. Methods This is a multicenter cohort study of women with IBD who underwent fecal calprotectin monitoring during pregnancy. Fecal calprotectin levels were stratified by trimester, and adverse pregnancy-related outcomes were recorded. The Mann-Whitney U test assessed differences between continuous variables, whereas categorical variables were compared using the Chi-squared test. Results Eighty-five women with IBD were included. First trimester fecal calprotectin was higher in patients who underwent emergency Cesarean birth compared to those who had a vaginal delivery (503 ug/g, IQR 1554.3 ug/g vs. 130 ug/g, IQR 482 ug/g,p = .030, respectively) and in those who delivered infants with low birth weight compared to normal birth weight (1511 ug/g, IQR 579 ug/g vs. 168 ug/g, IQR 413 ug/g,p = .049, respectively). Third trimester fecal calprotectin was higher in those with non-elective induction of labor (334.5 ug/g, IQR 1411.0 ug/g) compared to those with spontaneous delivery (116.5 ug/g, IQR 227.1 ug/g) (p = .025). Those with a fecal calprotectin >= 250 ug/g in the second trimester had an increased incidence of infants with low birth weight (35.3% vs. 3.8%) (p = .049), whereas those with a fecal calprotectin >= 250 ug/g in the third trimester had an increased incidence of non-elective induction of labor (43.8% vs. 10.3%,p = .030). Conclusions Fecal calprotectin may be a useful noninvasive marker to predict adverse pregnancy-related outcomes in patients with IBD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available